The concern of generic competition has repeatedly loomed above copyright’s famous drug, Sildenafil, sparking questions about the outlook of connected drug holdings. While first periods saw significant gains, the exclusivity lapse has allowed the path for cheaper copies, likely diminishing revenue and presenting a genuine danger for stakeholders s